指南与共识胃肠动力与功能性疾病

美国胃肠病学会与美国胃肠病学院临床实践指南:慢性特发性便秘的药物治疗

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.
指南 / 共识 · Am J Gastroenterol · 2023-05-19

美国胃肠病学会与美国胃肠病学院联合制定慢性特发性便秘(CIC)成人药物治疗指南,采用GRADE框架系统评价纤维、渗透性泻药、刺激性泻药、促分泌药及5-HT4激动剂等药物,最终形成10条推荐,其中聚乙二醇、匹可硫酸钠、利那洛肽、普芦卡必利等为强推荐。

要点

  • 聚乙二醇、匹可硫酸钠、利那洛肽、普芦卡必利获强推荐用于成人CIC。
  • 纤维、乳果糖、番泻叶、氧化镁、鲁比前列酮获条件性推荐。
  • 指南强调基于患者偏好、药物费用与可及性进行共享决策。

核心结论

  • 指南为成人CIC药物治疗提供循证推荐框架,共形成10条推荐。
  • 聚乙二醇、匹可硫酸钠、利那洛肽、普芦卡必利为强推荐。
  • 纤维、乳果糖、番泻叶、氧化镁、鲁比前列酮为条件性推荐。

研究设计与样本

  • 美国胃肠病学会与美国胃肠病学院组建多学科指南小组制定本指南。
  • 系统评价药物包括纤维、渗透性泻药、刺激性泻药、促分泌药及5-HT4激动剂。
  • 采用GRADE框架评估证据确定性,并基于证据到决策框架形成推荐。

主要发现

  • 指南小组就成人CIC药物治疗达成10条推荐。
  • 聚乙二醇、匹可硫酸钠、利那洛肽、普芦卡必利、普芦卡必利获强推荐。
  • 纤维、乳果糖、番泻叶、氧化镁、鲁比前列酮获条件性推荐。

关键数值与推荐

  • 聚乙二醇:强推荐用于成人CIC。
  • 匹可硫酸钠:强推荐用于成人CIC。
  • 利那洛肽:强推荐用于成人CIC。
  • 普芦卡必利:强推荐用于成人CIC。
  • 纤维、乳果糖、番泻叶、氧化镁、鲁比前列酮:条件性推荐用于成人CIC。

临床怎么用

  • 临床医生应基于患者偏好、药物费用与可及性进行共享决策。
  • 指南提供非处方与处方药物治疗CIC的综合框架。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic idiopathic constipation (CIC) is a common disorder associated with significant impairment in quality of life. This clinical practice guideline, jointly developed by the American Gastroenterological Association and the American College of Gastroenterology, aims to inform clinicians and patients by providing evidence-based practice recommendations for the pharmacological treatment of CIC in adults. METHODS: The American Gastroenterological Association and the American College of Gastroenterology formed a multidisciplinary guideline panel that conducted systematic reviews of the following agents: fiber, osmotic laxatives (polyethylene glycol, magnesium oxide, lactulose), stimulant laxatives (bisacodyl, sodium picosulfate, senna), secretagogues (lubiprostone, linaclotide, plecanatide), and serotonin type 4 agonist (prucalopride). The panel prioritized clinical questions and outcomes and used the Grading of Recommendations Assessment, Development, and Evaluation framework to assess the certainty of evidence for each intervention. The Evidence to Decision framework was used to develop clinical recommendations based on the balance between the desirable and undesirable effects, patient values, costs, and health equity considerations. RESULTS: The panel agreed on 10 recommendations for the pharmacological management of CIC in adults. Based on available evidence, the panel made strong recommendations for the use of polyethylene glycol, sodium picosulfate, linaclotide, plecanatide, and prucalopride for CIC in adults. Conditional recommendations were made for the use of fiber, lactulose, senna, magnesium oxide, and lubiprostone. DISCUSSION: This document provides a comprehensive outline of the various over-the-counter and prescription pharmacological agents available for the treatment of CIC. The guidelines are meant to provide a framework for approaching the management of CIC; clinical providers should engage in shared decision making based on patient preferences as well as medication cost and availability. Limitations and gaps in the evidence are highlighted to help guide future research opportunities and enhance the care of patients with chronic constipation.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Am J Gastroenterol. 2023. PMID: 37204227. doi:10.14309/ajg.0000000000002227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。